List view / Grid view
11 June 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...
10 June 2014 | By Myriad RBM
Institut Pasteur and Myriad RBM announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity...
9 June 2014 | By Merck
MSD and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which MSD will acquire Idenix for $24.50 per share in cash...
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
5 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV)...
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc., a privately held company, based in Mountain View, California, USA...
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
29 May 2014 | By SMI Group
Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs...
29 May 2014 | By SMI Group
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects...
29 May 2014 | By GTCBio
George Weinstock, Professor and Associate Director at The Jackson Laboratory for Genomic Medicine to give a keynote presentation on “Exploring the Role of the Microbiome in Disease”...
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
